AP NEWS

Exicure, Inc. to Present at Upcoming Investor Conference and Participate in Oncology Roundtable

September 28, 2018

SKOKIE, Ill.--(BUSINESS WIRE)--Sep 28, 2018--Exicure, Inc. (OTCQB:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the Ladenburg Thalmann 2018 Healthcare Conference and Leerink Partners Roundtable Series: Rare Disease & Oncology. Details of these presentations are as follows:

Ladenburg Thalmann 2018 Healthcare Conference

Date/Time: Tuesday, October 2, 2018 at 2:00 p.m. EDT Location: Sofitel Hotel, New York City

Leerink Partners Roundtable Series: Rare Disease & Oncology

Date/Time: Wednesday, October 3, 2018 at 9:30 a.m. EDT Location: Lotte New York Palace, New York City

A live webcast of these presentations will be available on the  Events & Presentations  section of Exicure’s website, where it will also be archived and available for replay following the presentation for 30 days.

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure’s proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure’s lead programs address oncology, inflammatory diseases and genetic disorders. Exicure is based outside of Chicago, IL. For more information, please visit www.exicuretx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005054/en/

CONTACT: Media Contact:

MacDougall Biomedical Communications

Karen Sharma, 781-235-3060

ksharma@macbiocom.com

or

Investor Contact:

The Del Mar Consulting Group, Inc.

Robert B. Prag, 858-794-9500

President

bprag@delmarconsulting.com

KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL

SOURCE: Exicure, Inc.

Copyright Business Wire 2018.

PUB: 09/28/2018 07:00 AM/DISC: 09/28/2018 07:00 AM

http://www.businesswire.com/news/home/20180928005054/en

AP RADIO
Update hourly